Overview

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acute myeloid leukaemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Institut de Recherches Internationales Servier
Collaborator:
ADIR, a Servier Group company
Treatments:
Azacitidine